Page last updated: 2024-11-01

norfloxacin and Constriction, Pathological

norfloxacin has been researched along with Constriction, Pathological in 1 studies

Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barrioz, T1
Ingrand, P1
Besson, I1
de Ledinghen, V1
Silvain, C1
Beauchant, M1

Trials

1 trial available for norfloxacin and Constriction, Pathological

ArticleYear
Randomised trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin.
    Lancet (London, England), 1994, Aug-27, Volume: 344, Issue:8922

    Topics: Administration, Oral; Bile Ducts; Cholestasis; Constriction, Pathologic; Drug Therapy, Combination;

1994